← brief for 2026-10-16 · Slowing decline

Monoclonal antibodies associated IgA nephropathy or other nephropathies

Key takeaways

This review covers how certain antibody drugs link to kidney diseases like IgA nephropathy. It is a summary of past work, not a new trial. There is no abstract, so no new results are available.

Who did this work

Miedziaszczyk M (Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences , ,) · Kosiorowski G (Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences , ,) · Kubasik J (Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences , ,) · Grabowski T (Department of Inorganic Chemistry, Medical University of Gdansk , ,) · Szałek E (Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences , ,) · Szeto C (Carol & Richard Yu Peritoneal Dialysis Research Centre, Prince of Wales Hospital, Department of Medicine & Therapeutics, The Chinese University of Hong Kong , ,) · Idasiak-Piechocka I (Department of General and Transplant Surgery, Poznan University of Medical Sciences , ,)

Source

Paper · Europe PMC, CKD · 2026-10-16
https://europepmc.org/article/PMC/PMC13662283